TY - JOUR
T1 - Immunologic and pharmacologic concepts of monoclonal antibodies
AU - Zuckier, Lionel S.
AU - Rodriguez, Lorna D.
AU - Scharff, Matthew D.
PY - 1989/7
Y1 - 1989/7
N2 - While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound under-standing of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.
AB - While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound under-standing of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.
UR - http://www.scopus.com/inward/record.url?scp=0024698430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024698430&partnerID=8YFLogxK
U2 - 10.1016/S0001-2998(89)80012-1
DO - 10.1016/S0001-2998(89)80012-1
M3 - Article
C2 - 2669128
AN - SCOPUS:0024698430
SN - 0001-2998
VL - 19
SP - 166
EP - 186
JO - Seminars in nuclear medicine
JF - Seminars in nuclear medicine
IS - 3
ER -